US 12,337,032 B2
Genetically stable recombinant modified vaccinia Ankara (RMVA) vaccines and methods of preparation thereof
Don J. Diamond, Glendora, CA (US); and Zhongde Wang, Mount Pleasant, SC (US)
Assigned to CITY OF HOPE, Duarte, CA (US)
Filed by CITY OF HOPE, Duarte, CA (US)
Filed on Nov. 28, 2022, as Appl. No. 18/059,117.
Application 14/075,975 is a division of application No. 12/795,621, filed on Jun. 7, 2010, granted, now 8,580,276, issued on Nov. 12, 2013.
Application 18/059,117 is a continuation of application No. 16/834,359, filed on Mar. 30, 2020, granted, now 11,541,114.
Application 16/834,359 is a continuation of application No. 15/589,857, filed on May 8, 2017, granted, now 10,603,375, issued on Mar. 31, 2020.
Application 15/589,857 is a continuation of application No. 14/075,975, filed on Nov. 8, 2013, granted, now 9,675,689, issued on Jun. 13, 2017.
Claims priority of provisional application 61/184,767, filed on Jun. 5, 2009.
Prior Publication US 2023/0293675 A1, Sep. 21, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 39/285 (2006.01); A61K 39/12 (2006.01); A61K 39/245 (2006.01); C07K 14/005 (2006.01); C12N 7/00 (2006.01); C12N 15/86 (2006.01); A61K 39/00 (2006.01)
CPC A61K 39/285 (2013.01) [A61K 39/12 (2013.01); A61K 39/245 (2013.01); C07K 14/005 (2013.01); C12N 7/00 (2013.01); C12N 15/86 (2013.01); A61K 2039/5256 (2013.01); C07K 2319/40 (2013.01); C12N 2710/16134 (2013.01); C12N 2710/16151 (2013.01); C12N 2710/24143 (2013.01); C12N 2830/60 (2013.01)] 16 Claims
 
1. An immunogenic composition comprising:
an immunologically effective amount of a recombinant modified vaccinia Ankara (rMVA) virus, wherein the rMVA virus comprises a fusion nucleotide sequence which encodes an IEfusion CMV protein antigen, said fusion nucleotide sequence comprising a nucleotide sequence comprising SEQ ID NO: 11.